The first commercial series of the drug manufactured in the new Medana production department, belonging to the Polpharma Group, was released for trading. This way, the company completed a 4-year investment period, which included a new facility for the production of non-sterile Iiquid forms, a new warehouse of packaging materials and raw materials, and a new R&D laboratory, where development projects in the field of inhalation drugs are carried out.